KR102275268B1 - Composition for relieving menopausal symptom or osteoporosis - Google Patents
Composition for relieving menopausal symptom or osteoporosis Download PDFInfo
- Publication number
- KR102275268B1 KR102275268B1 KR1020160065101A KR20160065101A KR102275268B1 KR 102275268 B1 KR102275268 B1 KR 102275268B1 KR 1020160065101 A KR1020160065101 A KR 1020160065101A KR 20160065101 A KR20160065101 A KR 20160065101A KR 102275268 B1 KR102275268 B1 KR 102275268B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- menopausal symptoms
- present
- food
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 61
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims description 139
- 238000000034 method Methods 0.000 claims description 31
- 230000036541 health Effects 0.000 claims description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 20
- 239000002537 cosmetic Substances 0.000 claims description 20
- 235000013376 functional food Nutrition 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 241000238424 Crustacea Species 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 230000006872 improvement Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229940107131 ginseng root Drugs 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 240000002234 Allium sativum Species 0.000 claims description 6
- 235000004611 garlic Nutrition 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 229940092738 beeswax Drugs 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 229940088597 hormone Drugs 0.000 abstract description 6
- 239000005556 hormone Substances 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 238000002657 hormone replacement therapy Methods 0.000 abstract description 2
- 231100001083 no cytotoxicity Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- 241000207199 Citrus Species 0.000 description 25
- 235000020971 citrus fruits Nutrition 0.000 description 25
- -1 etc.) Substances 0.000 description 25
- 235000013361 beverage Nutrition 0.000 description 19
- 230000009245 menopause Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000006071 cream Substances 0.000 description 15
- 239000006210 lotion Substances 0.000 description 13
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 235000013355 food flavoring agent Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002674 ointment Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 210000000963 osteoblast Anatomy 0.000 description 10
- 210000002997 osteoclast Anatomy 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 238000010609 cell counting kit-8 assay Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 235000013373 food additive Nutrition 0.000 description 8
- 239000002778 food additive Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000007901 soft capsule Substances 0.000 description 8
- 108010087230 Sincalide Proteins 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 206010060800 Hot flush Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000004072 osteoblast differentiation Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 235000016840 Citrus aurantium var. amara Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 244000240100 sour orange Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 244000003034 Arancio amaro Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 241001561395 Citrus natsudaidai Species 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 235000010804 Maranta arundinacea Nutrition 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 244000145580 Thalia geniculata Species 0.000 description 2
- 235000012419 Thalia geniculata Nutrition 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000010512 hydrogenated peanut oil Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000229175 Calotes Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241001481058 Citrus canaliculata Species 0.000 description 1
- 241001337999 Citrus iyo Species 0.000 description 1
- 241001001781 Citrus karna Species 0.000 description 1
- 241001573186 Citrus keraji Species 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 241000675139 Citrus pseudogulgul Species 0.000 description 1
- 241000694496 Citrus reshni Species 0.000 description 1
- 241000675136 Citrus sulcata Species 0.000 description 1
- 244000195654 Citrus taiwanica Species 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 241000333459 Citrus x tangelo Species 0.000 description 1
- 241001573191 Citrus yatsushiro Species 0.000 description 1
- DBPRUZCKPFOVDV-UHFFFAOYSA-N Clorprenaline hydrochloride Chemical compound O.Cl.CC(C)NCC(O)C1=CC=CC=C1Cl DBPRUZCKPFOVDV-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001126925 Lobata Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000269808 Sparus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010068313 Urethral atrophy Diseases 0.000 description 1
- 206010071018 Urogenital atrophy Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Abstract
본 발명은 여성 갱년기 증상 예방 및/또는 골다공증 개선, 예방 또는 치료용 조성물에 관한 것으로, 본 발명의 조성물은 여성 갱년기 증상 예방 또는 개선에 신속한 효과가 있으므로, 종래 갱년기 증상의 예방 또는 개선에 사용되는 호르몬 대체 요법(Hormone replacement therapy; HRT)에 유용하게 이용될 수 있다.
또한, 본 발명의 조성물은 종래의 여성 갱년기 증상에 대한 치료제와 달리 세포 독성도 없을 뿐만 아니라 식품으로 사용될 정도로 부작용이 적고, 안전하므로, 종래 여성 갱년기 증상에 대한 치료제에 비해 효과적으로 사용될 수 있다.The present invention relates to a composition for preventing or improving women's menopausal symptoms and/or osteoporosis, and since the composition of the present invention has a rapid effect on preventing or improving women's menopausal symptoms, a hormone used for preventing or improving conventional menopausal symptoms It can be usefully used for Hormone replacement therapy (HRT).
In addition, the composition of the present invention has no cytotoxicity, unlike conventional therapeutic agents for female menopausal symptoms, has few side effects enough to be used as food, and is safe, so it can be effectively used compared to conventional therapeutic agents for female menopausal symptoms.
Description
본 발명은 갈근 혼합 추출물을 포함하는 여성의 갱년기 증상 및/또는 골다공증의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving, or treating women's menopausal symptoms and/or osteoporosis, comprising the extract of the ginseng root mixture.
여성의 폐경(menopause)이란 태어난 후 약 50년에 이르는 유전적으로 이미 결정된 난소의 기능이 수명을 다함으로써 나타나는 월경의 중단 현상으로, 생식능력의 소실을 의미하며 병적 현상이 아닌 생리적인 변화이다. 현재 우리나라 여성의 평균 수명은 81.2세(2011년: 통계청)로 대한산부인과학회에서 규정한 한국 여성의 평균 폐경 연령을 50세로 가정한다면 여성 일생의 약 1/3 이상을 여성호르몬이 고갈된 상태로 산다는 것을 의미한다(약학정보원, 김성철).Menopause in women refers to the cessation of menstruation that occurs when the genetically determined ovarian function reaches the end of its life span for about 50 years after birth. It means loss of fertility and is a physiological change rather than a pathological phenomenon. Currently, the average lifespan of Korean women is 81.2 years (2011: Statistics Korea), and if the average age of menopause prescribed by the Korean Society of Obstetrics and Gynecology is 50, it is estimated that more than one third of a woman's life is spent in a state of depletion of female hormones. (Pharmaceutical Information Service, Kim Seong-cheol).
여성은 폐경을 맞이하면서 여성 호르몬의 분비 불균형 및 감소로 인해 혈관계, 근골격계, 비뇨생식기계 및 뇌신경 등 신체 전반에 걸쳐 변화가 일어난다. 즉 혈관 운동성증상과 심리적 증상인 안면 홍조, 야간 발한, 수면 장애, 피로감, 우울증, 불안감, 집중력 장애, 그리고 기억 장애와 비뇨생식계 위축에 의한 성교통, 빈뇨, 교원질 감소에 의한 피부탄력의 소실, 유방의 처짐, 그리고 심혈관 및 근골격계 증상, 치매 등의 다양한 질환 등이 동반된다(비특허문헌 1). 갱년기 증상은 개인마다 차이가 있지만 갱년기 증상을 많이 경험할수록, 정도가 심할수록, 그리고 기간이 길어질수록 여성의 삶의 질이 저하되는 것으로 보고되었을 뿐만(비특허문헌 2) 아니라, 갱년기 증상은 신체적인 노화와 함께 만성 질환으로 진행될 가능성이 높다.As women approach menopause, changes occur throughout the body, including the vascular system, musculoskeletal system, genitourinary system, and cranial nerve, due to imbalance and decrease in female hormone secretion. In other words, vasomotor symptoms and psychological symptoms such as hot flashes, night sweats, sleep disturbance, fatigue, depression, anxiety, difficulty concentrating, dyspareunia due to memory disturbance and urogenital atrophy, frequent urination, loss of skin elasticity due to collagen decrease, and breast It is accompanied by various diseases such as sagging, cardiovascular and musculoskeletal symptoms, dementia, and the like (Non-Patent Document 1). Although menopausal symptoms differ from person to person, it has been reported that the more experienced, the more severe, and the longer the duration of menopause symptoms, the lower the quality of life for women (Non-Patent Document 2). It is more likely to progress to chronic diseases with aging.
갱년기 증상의 치료에는 호르몬 요법, 약물 요법, 운동 요법, 식이요법이 적용될 수 있으나 의학적으로 많이 사용하는 여성 호르몬 치료는 유방암 등의 위험을 증가시킬 수 있으며, 장기간 사용시에는 자궁암, 혈전혈관질환, 담낭질환, 고혈압의 비율을 증가시킬 수 있다. 때문에 최근 들어서는 에스트로겐 요법과 기타 약물 요법 등의 대체를 위하여 에스트로겐과 유사한 기능을 하는 것으로 보고되고 있는 피토에스트로겐(phytoestrogen)에 대한 연구가 많이 이루어지고 있다(비특허문헌 3). Hormone therapy, drug therapy, exercise therapy, and diet can be applied to the treatment of menopausal symptoms, but female hormone therapy, which is widely used medically, may increase the risk of breast cancer, etc. , may increase the rate of hypertension. Therefore, in recent years, many studies have been conducted on phytoestrogen, which is reported to have a function similar to estrogen, in order to replace estrogen therapy and other drug therapies (Non-Patent Document 3).
갱년기 증상 개선과 관련된 선행 연구로는 당귀, 천궁, 백작약, 백출, 백봉령, 홍삼 및 대두추출물을 주성분으로 함유하며 갱년기 증상을 개선시킬 수 있는 기능성 식품(특허문헌 1), 및 황기, 결명자, 칡, 대두 추출물을 주성분으로 함유하는 식품으로 여성 갱년기 증상에 우수한 개선효과를 갖는 식품(특허문헌 2)이 있다.Prior studies related to the improvement of menopausal symptoms include angelica, cheongung, baekchul, baekbongryeong, red ginseng and soybean extract as main ingredients, and functional foods that can improve menopausal symptoms (Patent Document 1), and astragalus, kaleidoscope, arrowroot, As a food containing soybean extract as a main component, there is a food (Patent Document 2) having an excellent improvement effect on women's menopausal symptoms.
자연 폐경을 경험한 여성의 89%는 폐경 증상 중 적어도 하나를 경험하며, 갱년기 증상도 흔한 것으로 보고되고 있다. 이에 본 발명자들은 전반적인 갱년기 증상 완화와 갱년기로 인한 골다공증을 효과적으로 개선할 수 있는 천연물 소재를 개발하였고, 갈근 추출물과 지각 추출물의 혼합물로 이루어지는 여성 갱년기 증상 예방 또는 개선용 조성물을 완성하였다. 89% of women who experience spontaneous menopause experience at least one of the symptoms of menopause, and menopausal symptoms are also reported to be common. Accordingly, the present inventors have developed a natural material that can effectively alleviate menopausal symptoms and effectively improve osteoporosis due to menopause, and have completed a composition for preventing or improving female menopausal symptoms comprising a mixture of extracts of ginseng root and crustaceans.
본 발명은 여성 갱년기의 전반적인 증상 및/또는 골다공증을 예방, 개선 또는 치료하는데 효과적인 조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a composition effective for preventing, ameliorating or treating the general symptoms of female menopause and/or osteoporosis.
본 발명에서는 갈근 추출물 및 지각 추출물을 포함하는 갱년기 증상 및/또는 골다공증의 예방, 치료 또는 개선용 조성물을 제공한다. The present invention provides a composition for the prevention, treatment or improvement of menopausal symptoms and/or osteoporosis, comprising the extract of rhubarb root and crustaceans.
상기 조성물은 식품 조성물, 약학 조성물 또는 화장료 조성물 일 수 있다. The composition may be a food composition, a pharmaceutical composition or a cosmetic composition.
또한, 본 발명은 상기 추출물을 포함하는 건강 기능 식품을 제공한다.In addition, the present invention provides a health functional food containing the extract.
또한, 본 발명은 상기 조성물을 포함하는 화장품, 의약품 및/또는 의약외품을 제공한다.In addition, the present invention provides a cosmetic, pharmaceutical and/or quasi-drug comprising the composition.
본 발명에 따른 조성물은 여성 갱년기 증상 및/또는 골다공증의 예방 또는 개선에 신속한 효과가 있으므로, 종래 갱년기 증상의 예방 또는 개선에 사용되는 호르몬 대체 요법(Hormone replacement therapy; HRT)에 유용하게 이용될 수 있다.Since the composition according to the present invention has a rapid effect on the prevention or improvement of female menopausal symptoms and/or osteoporosis, it can be usefully used for hormone replacement therapy (HRT) used for the prevention or improvement of conventional menopausal symptoms. .
또한, 본 발명에 따른 조성물은 여성 갱년기 증상이나 골다공증에 대한 종래의 치료제와 달리 세포 독성도 없을 뿐만 아니라 식품으로 사용될 정도로 부작용이 적고, 안전하므로, 종래 여성 갱년기 증상 및/또는 골다공증에 대한 치료제로 그 활용도가 높다.In addition, the composition according to the present invention does not have cytotoxicity unlike conventional therapeutic agents for female menopausal symptoms or osteoporosis, and has few side effects and is safe enough to be used as food, so it is used as a therapeutic agent for conventional female menopausal symptoms and/or osteoporosis. The usability is high.
도 1은 본 발명의 일 실시예에 따른 혼합 추출물의 에스트로겐 수용체 양성 인간 유방암 세포주에 대한 세포 활성도를 나타내는 그래프이다.
도 2는 본 발명의 일 실시예에 따른 본 발명의 혼합 추출물의 조골세포에 대해 증식 촉진 효과를 나타내는 그래프이다
도 3은 본 발명의 일 실시예에 따른 혼합 추출물의 조골세포에 대해 분화 촉진 효과를 나타내는 그래프이다.
도 4는 본 발명의 일 실시예에 따른 혼합 추출물의 파골 세포에 대해 증식 억제 효과를 나타내는 그래프이다.1 is a graph showing the cell activity of a mixed extract according to an embodiment of the present invention against an estrogen receptor-positive human breast cancer cell line.
2 is a graph showing the proliferation promoting effect on osteoblasts of the mixed extract of the present invention according to an embodiment of the present invention;
3 is a graph showing the differentiation promoting effect on osteoblasts of the mixed extract according to an embodiment of the present invention.
4 is a graph showing the proliferation inhibitory effect on osteoclasts of the mixed extract according to an embodiment of the present invention.
본 발명은 갈근 추출물 및 지각 추출물을 포함하는 갱년기 증상의 예방, 개선 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing, ameliorating or treating menopausal symptoms, comprising the extract of ginseng root and crustacean extract.
또한, 본 발명은 갈근 추출물 및 지각 추출물을 포함하는 골다공증의 예방, 개선 또는 치료용 조성물에 관한 것이다.In addition, the present invention relates to a composition for preventing, improving, or treating osteoporosis, comprising the extract of rhubarb root and crustaceans.
이하, 본 발명에 따른 조성물을 보다 상세하게 설명한다.Hereinafter, the composition according to the present invention will be described in more detail.
본 발명의 일 실시예에서, 갈근 추출물과 지각 추출물의 혼합 추출물을 유방암 세포주(MCF-7 cell line)에 처리하여 세포의 활성도가 향상되고, 쿠퍼만 지수를 활용하여 본 발명의 추출물을 직접 복용한 결과, 갱년기 증상을 개선함을 실험적으로 확인 하였다(실험예 1 및 5). 또한, 본 발명의 혼합 추출물을 조골세포 유사 세포(MG-63 cell)에 처리한 경우 조골세포의 증식이 촉진되고, 이와 반대로 파골세포 에서는 증식을 억제한다는 것을 실험적으로 확인하였다(실험예 2 내지 4).In one embodiment of the present invention, the cell activity is improved by treating the mixed extract of the extract of the ginseng extract and the crustacean extract in a breast cancer cell line (MCF-7 cell line), and the extract of the present invention is directly taken using the Kupperman index. As a result, it was confirmed experimentally that the menopausal symptoms were improved (Experimental Examples 1 and 5). In addition, when the mixed extract of the present invention was treated with osteoblast-like cells (MG-63 cells), the proliferation of osteoblasts was promoted, and on the contrary, it was experimentally confirmed that the proliferation was inhibited in osteoclasts (Experimental Examples 2 to 4) ).
따라서, 본 발명의 혼합 추출물은 갱년기 증상과 골다공증을 동시에 치료 또는 개선할 수 있으므로, 본 발명의 조성물은 갈근 추출물 및 지각 추출물을 포함하는 갱년기 증상 및 골다공증 예방, 치료 또는 개선용 조성물 일 수 있다. Therefore, since the mixed extract of the present invention can treat or improve menopausal symptoms and osteoporosis at the same time, the composition of the present invention may be a composition for preventing, treating or improving menopausal symptoms and osteoporosis, including the extract of the ginseng root and the crustaceans.
본 발명에 따른 갱년기 증상 및/또는 골다공증의 예방 또는 개선용 조성물은 전술한 바와 같이, 혼합 추출물을 포함한다. 상기 혼합 추출물은 갈근 추출물 및 지각 추출물을 포함한다. 보다 구체적으로, 상기 혼합 추출물은 갈근 및 지각의 혼합 추출물 As described above, the composition for preventing or improving menopausal symptoms and/or osteoporosis according to the present invention includes a mixed extract. The mixed extract includes extracts of garlic root and crustaceans. More specifically, the mixed extract is a mixed extract of ground root and crust
상기 혼합 추출물은 갈근 추출물 10중량부에 대하여, 지각 추출물을 1 내지 100 중량부로 포함할 수 있다. 바람직하게는 갈근 10 중량부에 대하여 지각 추출물을 5 중량부 내지 50 중량부, 더욱 바람직하게는 8 중량부 내지 20 중량부로 포함할 수 있다. 본 발명의 일 실시예에서 갈근 및 지각 추출물을 1:1로 포함하는 혼합 추출물의 경우 단독 추출물 보다 훨씬 여성 갱년기 증상 및 골다공증에서 개선 또는 예방 효과가 우수한 것을 확인하였다.The mixed extract may contain 1 to 100 parts by weight of the crust extract based on 10 parts by weight of the extract of the ginseng root. Preferably, the crust extract may be included in an amount of 5 to 50 parts by weight, more preferably 8 to 20 parts by weight, based on 10 parts by weight of brown root. In an embodiment of the present invention, it was confirmed that the mixed extract containing the extracts of brown root and crustaceans in a 1:1 ratio was superior to the single extract in improving or preventing the symptoms of female menopause and osteoporosis.
또한, 상기 갈근 및 지각 혼합 추출물은 갈근 추출물 10 중량부에 대하여 지각 추출물을 1 내지 100 중량부로 더 포함할 수 있고, 바람직하게는 5 내지 50 중량부, 더욱 바람직하게는 8 내지 20 중량부로 포함할 수 있다. In addition, the brown root and crust mixed extract may further include 1 to 100 parts by weight of the crust extract based on 10 parts by weight of the brown root extract, preferably 5 to 50 parts by weight, more preferably 8 to 20 parts by weight. can
본 발명에서 '갈근(Puerariae Radix)'은 콩과(Leguminosae)에 속한 다년생 덩굴성 초본인 칡(Pueraria lobata)의 뿌리로, 해기퇴열(解肌退熱), 생진(生津), 투진(透疹) 및 승양지사(升陽止瀉)의 효능으로 한방임상에 널리 사용하는 한약재이다. 갈근은 이소플라본(isoflavone)에 속하는 다양한 화합물을 포함하고 있다. In the present invention, ' Puerariae Radix ' is a perennial creeping herb belonging to Leguminosae, arrowroot ( Pueraria). lobata ), it is a herbal medicine widely used in oriental medicine clinical practice due to its effects of regurgitation, saengjin (生津), tussine (透疹) and elevating branch (升阳止瀉). Garlic contains various compounds belonging to isoflavones.
본 발명에서 '지각(Citri Furctus)'은 운향과에 속한 광귤나무(Citrus aurantum), 하귤(Citrus natsudaidai) 또는 그 재배변종(운향과 Rutaceae)의 과실을 의미한다. 주성분으로 플라본(flavanone)과 플라보노이드(flavonoid)에 속하는 다양한 화합물이 분리되었고, 항산화 및 항염증에 효과가 있다고 보고되어 있다. 지각의 구체적인 예로, Aurantium acre, Aurantium bigarella, Aurantium corniculatum, Aurantium corniculatum, Aurantium coronatum, Aurantium distortum, Aurantium humile, Aurantium myrtifolium, Aurantium orientale, Aurantium Silvestre, Aurantium sinense, Aurantium variegatum, Aurantium vulgare, Citrus bigaradia, Citrus humilis, Citrus amara, Citrus aurata, Citrus benikoji, Citrus bigaradia, Citrus calot, Citrus canaliculata, Citrus changshan - huyou, Citrus communis, Citrus dulcimedulla, Citrus dulcis, Citrus florida, Citrus funadoko, Citrus fusca, Citrus glaberrima, Citrus humilis, Citrus intermedia, Citrus iwaikan, Citrus iyo, Citrus karna, Citrus keraji, Citrus kotokan, Citrus medioglobosa, Citrus mitsuharu, Citrus myrtifolia, Citrus natsudaidai, Citrus omikanto, Citrus pseudogulgul, Citrus reshni, Citrus rokugatsu, Citrus rumphii, Citrus sinograndis, Citrus subcompressa, Citrus sulcata, Citrus taiwanica, Citrus tangelo, Citrus tengu, Citrus tosa -asahi, Citrus truncate, Citrus vulgaris, Citrus yatsushiro, 및 Citrus yuge - hyokan을 포함하나, 상기 예에 제한되는 것은 아니다. 상기 지각은 상업적으로 판매되는 것을 구입하거나, 자연계에서 재배 또는 채취한 것을 모두 포함한다.In the present invention, 'Citri Furctus' refers to the fruit of Citrus aurantum, Citrus natsudaidai, or its cultivars (Rutaceae) belonging to the rutaceae family. Various compounds belonging to flavones and flavonoids as main components have been isolated, and it is reported that they are effective in antioxidant and anti-inflammatory properties. A specific example of crust, Aurantium acre , Aurantium bigarella , Aurantium corniculatum , Aurantium corniculatum , Aurantium coronatum , Aurantium distortum , Aurantium humile , Aurantium myrtifolium , Aurantium orientale , Aurantium Silvestre , Aurantium sinense , Aurantium variegatum , Aurantium vulgare, Citrus bigaradia, Citrus humilis, Citrus amara, Citrus aurata, Citrus benikoji, Citrus bigaradia, Citrus calot, Citrus canaliculata, Citrus changshan - huyou, Citrus communis, Citrus dulcimedulla, Citrus dulcis, Citrus florida, Citrus funadoko, Citrus fusca, Citrus glaberrima, Citrus humilis, Citrus intermedia, Citrus iwaikan, Citrus iyo, Citrus karna, Citrus keraji, Citrus kotokan, Citrus medioglobosa, Citrus mitsuharu, Citrus myrtifolia , Citrus natsudaidai, Citrus omikanto, Citrus pseudogulgul, Citrus reshni, Citrus rokugatsu, Citrus rumphii, Citrus sinograndis, Citrus subcompressa, Citrus sulcata, Citrus taiwanica, Citrus tangelo, Citrus tengu, Citrus tosa -asahi, Citrus truncate , Citrus vulgaris , Citrus yatsushiro , and Citrus yuge - hyokan , but are not limited to the above examples. The crust includes all those purchased commercially sold, or grown or harvested in nature.
본 발명에서 '추출물'은 식물체 등을 추출용매로 추출하거나 추출용매로 추출하여 제조한 추출물에 분획용매를 가하여 분획하여 제조할 수 있다. In the present invention, the 'extract' can be prepared by extracting a plant body with an extraction solvent or by adding a fractionation solvent to an extract prepared by extracting it with an extraction solvent.
상기 추출물 또는 분획물은, 상기 추출물의 희석이나 농축, 상기 추출물을 건조하여 얻어지는 건조물, 상기 추출물의 조정제물이나 정제물 또는 이들의 혼합물 등 추출물 자체와 추출물을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 구체적으로 본 발명의 추출물은 추출 후 건조 분말 형태로 제조되어 사용될 수 있다. 또한, 추출 또는 분획과정을 수행한 이후, 감압 여과 과정을 수행하거나 추가로 농축 및/또는 동결건조를 수행하여 농축하거나 용매를 제거할 수 있다. 상기 수득한 추출물은 사용시까지 급속 냉동 냉장고(deep freezer)에 보관할 수 있다.The extract or fraction includes extracts of all formulations that can be formed using the extract itself and the extract, such as dilution or concentration of the extract, a dried product obtained by drying the extract, a prepared or purified product of the extract, or a mixture thereof. . Specifically, the extract of the present invention may be prepared and used in the form of a dry powder after extraction. In addition, after performing the extraction or fractionation process, a reduced pressure filtration process or additional concentration and/or freeze-drying may be performed to concentrate or remove the solvent. The obtained extract may be stored in a deep freezer until use.
본 발명의 추출물에 사용되는 상기 식물체는 식물의 천연, 잡종 또는 변종 식물 및 식물 조직의 배양체와 배양물을 모두 포함한다. The plants used in the extract of the present invention include both natural, hybrid or mutated plants of plants and cultures and cultures of plant tissues.
상기 추출용매의 종류는 특별히 제한되지 아니하며, 본 발명의 목적 효과를 갖는 추출물을 수득할 수 있는 한 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 구체적으로, 물 및 유기용매로 이루어진 군에서 선택된 1종 이상 일 수 있다. 상기 유기용매는 메탄올, 에탄올 등의 탄소수 1 내지 5의 알코올, 에틸아세테이트, 아세톤 및 클로로포름으로 이루어진 군으로부터 선택된 하나 이상의 용매를 사용할 수 있다. The type of the extraction solvent is not particularly limited, and any solvent known in the art may be used as long as an extract having the desired effect of the present invention can be obtained. Specifically, it may be at least one selected from the group consisting of water and an organic solvent. As the organic solvent, one or more solvents selected from the group consisting of alcohols having 1 to 5 carbon atoms such as methanol and ethanol, ethyl acetate, acetone, and chloroform may be used.
바람직하게는 물을 사용할 수 있다. 구체적인 실시예에서, 정제수를 이용하여 추출한 갈근과 지각의 혼합 추출물을 이용하여 갱년기 증상 개선 정도를 확인한 결과, 상기 혼합 추출물로 처리된 세포의 생존력, 조골세포 분화 및 증식능력이 향상 되었고, 혼합 추출물을 섭취한 실험군의 갱년기 증상이 개선됨을 확인 하였다. Preferably, water can be used. In a specific example, as a result of checking the degree of improvement in menopausal symptoms using a mixed extract of brown root and crust extracted using purified water, the viability, osteoblast differentiation and proliferation ability of cells treated with the mixed extract were improved, and the mixed extract It was confirmed that the menopausal symptoms of the ingested experimental group were improved.
상기 분획용매는 물, 부탄올, 에틸아세테이트, 클로로포름, 헥산 또는 이들의 혼합물일 수 있다. 상기 분획물은 상기 추출법으로 제조한 추출물, 구체적으로 조추출액에 분획과정을 더욱 실시한 분획물일 수 있다. 상기 분획용매는 에틸아세테이트, 에테르, 클로로포름, 벤젠, 헥산, 메틸렌클로라이드 및 이들의 혼합용매로 이루어진 군에서 선택된 용매일 수 있으며, 바람직하게는 헥산일 수 있다. 상기 분획과정은 구체적으로 상기 조추출액에 헥산, 플로로포름, 에틸아세테이트, 부탄올 및 물을 순서로 가한 후에, 층 분리한 헥산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, 부탄올 분획물 및 물 분획물을 순차적으로 수득하는 방법으로 수행할 수 있다.The fractionation solvent may be water, butanol, ethyl acetate, chloroform, hexane, or a mixture thereof. The fraction may be an extract prepared by the above extraction method, specifically, a fraction obtained by further subjecting the crude extract to a fractionation process. The fractionation solvent may be a solvent selected from the group consisting of ethyl acetate, ether, chloroform, benzene, hexane, methylene chloride, and a mixed solvent thereof, preferably hexane. In the fractionation process, hexane, fluoroform, ethyl acetate, butanol and water were sequentially added to the crude extract, followed by layer-separated hexane fraction, chloroform fraction, ethyl acetate fraction, butanol fraction and water fraction were sequentially obtained can be done in this way.
본 발명에서 추출물의 제조방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있고, 이들을 단독으로 수행하거나 2종 이상의 방법을 함께 수행할 수 있다. 또한, 고순도의 추출물을 얻기 위하여 추출액을 간은 방법으로 1회 이상씩 더 추출 할 수도 있다. The method for preparing the extract in the present invention is not particularly limited, and it may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, and these may be performed alone or two or more methods may be performed together. In addition, in order to obtain a high-purity extract, the extract may be further extracted one or more times in a seasoned method.
본 발명에서 '갱년기 증상'이란, 난소의 노화 등으로 인하여 에스트로겐의 분비가 감소됨에 따라 폐경을 전후로 여성에게서 나타나는 증상 및 질환을 총칭한다. '갱년기 증후군' 또는 '폐경기 증상' 이라고도 불린다. 갱년기 또는 폐경기 증상은 예를 들어, 안면홍조, 발한, 신경질, 우울증, 어지럼증, 피로감, 관절통, 근육통, 두통, 가슨 두근거림, 의주감, 수면 중 발한, 수면 장애, 피부 건조, 질 건조증, 질 위축, 하부 요도 위축, 성교 통, 질염, 방광염, 배뇨통, 급뇨, 집중 장애, 기억력 장애, 불안, 신경 과민, 기억력 감퇴, 피부건조, 관절통 또는 골다공증 등이 있으며 이에 한정되지 않는다. 또한, 심장병, 고혈압, 뇌졸중과 같은 심혈관계 이상일 수도 있다. In the present invention, 'menopausal symptoms' refers to symptoms and diseases that appear in women before and after menopause due to decreased estrogen secretion due to ovarian aging. It is also called 'menopausal syndrome' or 'menopausal symptoms'. Menopause or menopause symptoms include, for example, hot flashes, sweating, nervousness, depression, dizziness, fatigue, joint pain, muscle pain, headache, light palpitations, feeling of tightness, sweating during sleep, sleep disturbance, dry skin, vaginal dryness, vaginal atrophy , lower urethral atrophy, dyspareunia, vaginitis, cystitis, dysuria, urgency, difficulty concentrating, memory impairment, anxiety, nervousness, memory loss, dry skin, joint pain, or osteoporosis, and the like. It may also be a cardiovascular disorder such as heart disease, high blood pressure, or stroke.
본 발명에서 '골다공증' 이란, 뼈의 강도가 약해져서 골절이 일어날 가능성이 높은 상태를 의미하는 것으로, 유전적 요인, 조기 폐경, 약제 또는 흡연 등이 원인이 된다. 따라서, 여성의 폐경 등에 의하여 호르몬 생산의 감소로 인해 나타나는 '갱년기 골다공증'일 수 있다. 갱년기 골다공증이란 폐경기 여성에게서 호르몬 생산의 감소로 인해 뼈 형성에 관여하는 조골세포와 조직의 파괴와 흡수에 관여하는 파골세포의 불균형에 의해 발생하는 골다공 증상을 의미한다. In the present invention, 'osteoporosis' refers to a condition in which bone strength is weakened and fractures are highly likely, and is caused by genetic factors, early menopause, drugs or smoking. Therefore, it may be 'menopausal osteoporosis' caused by a decrease in hormone production due to menopause in women. Menopausal osteoporosis refers to osteoporosis symptoms caused by an imbalance between osteoblasts involved in bone formation and osteoclasts involved in tissue destruction and resorption in postmenopausal women due to a decrease in hormone production.
본 발명에서 '예방'이란 본 발명의 조성물을 투여하여 목적하는 증상을 억제 또는 지연시키는 모든 행위를 의미한다. In the present invention, 'prevention' means any action that suppresses or delays a desired symptom by administering the composition of the present invention.
본 발명에서 '치료'란 본 발명의 조성물을 투여하여 목적하는 증상 또는 질병을 호전시키거나 사라지게 되는 모든 행위를 의미한다. In the present invention, 'treatment' refers to any action that improves or disappears a desired symptom or disease by administering the composition of the present invention.
본 발명에서 '개선'이란 본 발명의 조성물을 투여하여 목적하는 증상을 투여 전 보다 증세가 호전 또는 이롭게 변경되는 모든 행위를 의미한다.In the present invention, 'improvement' refers to any action in which the symptoms are improved or changed advantageously compared to before administration of the desired symptoms by administering the composition of the present invention.
본 발명의 조성물에 포함되는 추출물의 함량은 유효량으로 포함될 수 있다. 상기 용어 '유효량'은 갱년기 증상 또는 골다공증을 억제 또는 지연시키거나, 이미 나타난 증상을 호전시킬 수 있는, 또는 조골세포의 분화 및 증식을 촉진시키는 효과를 추출물의 양을 의미한다The content of the extract included in the composition of the present invention may be included in an effective amount. The term 'effective amount' refers to the amount of the extract that can suppress or delay menopausal symptoms or osteoporosis, improve the symptoms already appeared, or promote the differentiation and proliferation of osteoblasts.
상기 조성물에 포함되는 상기 혼합 추출물의 함량은 갱년기 증상 또는 골다공증을 예방, 개선 또는 치료할 수 있다면 다양한 중량%로 포함될 수 있다. 구체적으로 전체 조성물에 대하여, 갈근 추출물은 0.001 내지 30 중량%, 지각 추출물은 0.001 내지 30 중량%를 포함할 수 있다. 각 유효성분이 하한 미만으로 포함되는 경우에는 여성 갱년기 증상 또는 골다공증의 예방, 치료 또는 개선 효능이 발휘되지 않을 수 있으며, 상한 초과로 포함되는 경우에는 유효성분 자체의 물성, 색 및 특유의 향미가 제품에 영향을 줄 수 있다.The content of the mixed extract included in the composition may be included in various weight % if it can prevent, improve or treat menopausal symptoms or osteoporosis. Specifically, with respect to the entire composition, the extract of the ginseng root may contain 0.001 to 30% by weight, and the crust extract may include 0.001 to 30% by weight. If each active ingredient is included below the lower limit, the efficacy of preventing, treating, or improving female menopausal symptoms or osteoporosis may not be exhibited. can affect
또한, 본 발명의 일 실시예에 따라, 상기 조성물은 상기 혼합 추출물을 조성물 1kg에 대하여 1mg 내지 1000 mg으로 포함할 수 있고, 바람직하게는 5 mg 내지 500mg, 더욱 바람직하게는 5 mg 내지 100 mg으로 포함할 수 있다. In addition, according to an embodiment of the present invention, the composition may include 1 mg to 1000 mg of the mixed extract with respect to 1 kg of the composition, preferably 5 mg to 500 mg, more preferably 5 mg to 100 mg may include
본 발명에 따른 조성물은 혼합 추출물을 포함하는 갱년기 증상 또는 골다공증의 예방 또는 개선용 식품 조성물일 수 있다. The composition according to the present invention may be a food composition for preventing or improving menopausal symptoms or osteoporosis, including a mixed extract.
또한, 본 발명은 상기 조성물을 포함하는 갱년기 증상 또는 골다공증의 예방 또는 개선용 식품을 제공한다. In addition, the present invention provides a food for preventing or improving menopausal symptoms or osteoporosis comprising the composition.
본 발명의 식품 조성물에 포함되는 갈근 및 지각은 천연 물질로서 오랫동안 사용되어 안정성이 입증되었으므로, 일상적으로 섭취가 가능한 식품의 형태로 제조하여 섭취할 수 있으므로, 갱년기 증상 및 골다공증 예방 또는 개선에서 높은 효과를 기대할 수 있다. Since the brown root and crust contained in the food composition of the present invention have been used as natural substances for a long time and have proven their stability, they can be prepared and consumed in the form of foods that can be consumed on a daily basis, so they have a high effect in preventing or improving menopausal symptoms and osteoporosis. can be expected
상기 '식품'은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서 건강 기능 식품, 기능성 식품, 음료, 식품 첨가제 및 음료 첨가제를 모두 포함하는 의미이다.The 'food' means a natural product or processed product containing one or more nutrients, and preferably means a state that can be eaten directly through a certain amount of processing, and as a general meaning, a health functional food, It is meant to include all functional foods, beverages, food additives and beverage additives.
상기 식품은 통상적인 의미의 식품을 모두 포함하며, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능 식품 등일 수 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영, 유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실 및 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면스프 등)를 포함하나 이에 한정되지 않는다.The food includes all foods in a conventional sense, and may be, for example, various foods, beverages, gum, tea, vitamin complexes, health functional foods, and the like. In addition, in the present invention, foods include special nutritional foods (eg, formula milk, young, baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplements, seasoned foods ( Ex, soy sauce, soybean paste, red pepper paste, mixed soy sauce, etc.), sauces, sweets (eg snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruit and vegetable beverages, soy milk, fermented beverages, etc.) and natural seasonings (eg, ramen soup, etc.).
상기 식품, 기능성 식품, 건강 기능 식품, 음료, 식품 첨가제 및 음료 첨가제는 통상의 제조방법으로 제조될 수 있다.The food, functional food, health functional food, beverage, food additive and beverage additive may be prepared by a conventional manufacturing method.
상기 기능성 식품(functional food)이란, 특정보건용 식품(food for special health use, FoSHU)와 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 기능성 식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 기능성 식품의 제형 또한 기능성 식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품용 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 기능성 식품은 갱년기 증상 또는 골다공증의 예방 또는 개선의 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The functional food is the same term as food for special health use (FoSHU), and refers to a food with high medical and medical effects processed to efficiently exhibit bioregulatory functions in addition to nutrition supply. . Herein, the term "functionality" refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological actions with respect to the structure and function of the human body. The functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, the formulation of the functional food may be prepared without limitation as long as it is a formulation recognized as a functional food. The composition for food of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur during long-term administration of the drug using food as a raw material, and has excellent portability, and the present invention Functional food of can be consumed as a supplement to enhance the effect of preventing or improving menopausal symptoms or osteoporosis.
본 발명에서 건강 기능 식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절 기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. 일반식품에 비해 적극적인 건강유지나 증진 효과를 가지고, 건강 보조 식품(health supplement food)은 건강보조 목적의 식품을 의미한다. 경우에 따라, 기능성 식품, 건강 식품, 건강 보조 식품의 용어는 혼용된다.In the present invention, health functional food is a food group or food composition that has added value to act and express the function of the food for a specific purpose using physical, biochemical, and bioengineering methods, etc. It refers to food that is designed and processed to sufficiently express body control functions related to recovery, etc. It has an active health maintenance or promotion effect compared to general food, and health supplement food means food for the purpose of health supplementation. In some cases, the terms functional food, health food, and dietary supplement are used interchangeably.
구체적으로, 상기 건강 기능 식품은 본 발명의 추출물 또는 이의 분획물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용이 없는 장점이 있다.Specifically, the health functional food is a food prepared by adding the extract of the present invention or a fraction thereof to food materials such as beverages, teas, spices, gums, and confectionery, or encapsulating, powdering, suspension, etc., when ingested. It means that it has a specific effect on health, but unlike general drugs, it has the advantage of not having side effects that may occur when taking a drug for a long period of time using food as a raw material.
본 발명의 건강 기능 식품에는 상기 조성물을 건강 기능 식품 총 중량% 대비 1 내지 70 중량%로 포함할 수 있으며, 바람직하게는 1 내지 15 중량%로 포함할 수 있다.The health functional food of the present invention may include the composition in an amount of 1 to 70% by weight, preferably 1 to 15% by weight, based on the total weight% of the health functional food.
상기 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 건강 기능 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다. The food may include a food additive that is pharmaceutically acceptable, and may further include suitable carriers, excipients and diluents commonly used in the manufacture of health functional foods.
상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu), 크륨(Cr) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. The composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, and the like may be included. Also, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr). In addition, it may include amino acids such as lysine, tryptophan, cysteine, and valine.
상기 조성물은 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The composition comprises a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), a disinfectant (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), an antioxidant (butylhydroxyanisole (BHA), butylhydroxytoluene, etc.) (BHT), etc.), coloring agents (tar pigments, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclimate, saccharin, sodium, etc.) ), flavorings (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (foams), film agents, gum base agents, foam inhibitors, solvents, food additives such as improving agents additives). The additive may be selected according to the type of food and used in an appropriate amount.
본 발명의 추출물 또는 이의 분획물을 식품첨가물로 사용하는 경우, 추출물 또는 이의 분획물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 장기간 섭취할 경우에는 상기 범위 이하의 함량을 포함할 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the extract or a fraction thereof of the present invention is used as a food additive, the extract or a fraction thereof may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). In general, in the production of food or beverage, the food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, when ingested for a long period of time for health and hygiene purposes, it may contain an amount below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
본 발명은 식품 조성물의 일 예로 건강음료 조성물로 사용될 수 있다.The present invention may be used as an example of a food composition as a health drink composition.
본 발명에서 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며, 건강 기능 음료를 포함하는 의미이다.In the present invention, beverage means a generic term for drinking to quench thirst or enjoy taste, and includes health functional beverages.
상기 음료는 지시된 비율로 필수 성분으로서 상기 추출물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. The beverage is not particularly limited in other ingredients other than containing the extract as an active ingredient as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage.
상기의 천연 탄수화물의 예는 포도당이나 과당 등과 같은 모노사카라이드, 말토스, 수크로스 등과 같은 디사카라이드, 덱스트린, 시클로덱스트린 등과 같은 폴리사카라이드 또는 자일리톨, 소르비톨, 에리트리톨 등의 당알코올 등일 수 있다. 상기 향미제는 타우마틴이나 레바우디오시드 A 또는 글리시르히진과 같은 스테비아 추출물과 같은 천연 향미제 또는 사카린, 아스파르탐 등과 같은 합성 향미제일 수 있다.Examples of the natural carbohydrate include monosaccharides such as glucose or fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, or sugar alcohols such as xylitol, sorbitol, erythritol, etc. . The flavoring agent may be a natural flavoring agent such as stevia extract such as thaumatin or rebaudioside A or glycyrrhizin, or a synthetic flavoring agent such as saccharin or aspartame.
상기 천연 탄수화물의 첨가량은 본 발명의 식품 조성물 100 ㎖ 당 일반적으로 약 1 g 내지 20 g, 바람직하게는 5 g 내지 12 g일 수 있다. 그밖에 본 발명의 조성물은 천연 과일 주스, 과일 쥬스 음료, 야채 음료의 제조를 위한 과육을 추가로 함유할 수 있다.The amount of the natural carbohydrate added may be generally about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the food composition of the present invention. In addition, the composition of the present invention may further contain pulp for the production of natural fruit juice, fruit juice beverage, and vegetable beverage.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등의 첨가제를 함유할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and It may contain additives such as salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The proportion of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
상기 건강 기능 음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다. The health functional beverage is a beverage group or beverage composition that has added value to act and express the function of the beverage for a specific purpose using physical, biochemical, and bioengineering methods, etc., to control biological defense rhythm, prevent disease and recover. It refers to a beverage designed and processed to sufficiently express the body control functions related to the living body.
상기 건강 기능 음료는 지시된 비율로 필수 성분으로서 본 발명의 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health functional beverage is not particularly limited in other ingredients except for containing the extract of the present invention as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage.
상기 식품은 식품첨가물을 추가로 포함할 수 있고, 식품첨가물로서의 적합여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The above food may additionally contain food additives, and, unless otherwise specified, whether it is suitable as a food additive according to the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety and standards and standards for the item judged by
또한, 본 발명에 따른 조성물은 혼합 추출물을 포함하는 갱년기 증상 또는 골다공증 예방 또는 치료용 약학적 조성물 일 수 있다. In addition, the composition according to the present invention may be a pharmaceutical composition for preventing or treating menopausal symptoms or osteoporosis including a mixed extract.
또한, 본 발명은 상기 약학적 조성물을 포함하는 의약품 또는 의약외품에 관한 것이다.In addition, the present invention relates to a pharmaceutical or quasi-drug comprising the pharmaceutical composition.
일 실시예에 따라, 본 발명의 혼합 추출물을 유방암 세포주(MCF-7 cell line)에 처리하여 세포의 생존력이 향상되는 것을 확인 하였고, 쿠퍼만 지수를 활용하여 본 발명의 추출물을 직접 복용한 결과, 갱년기 증상을 개선함을 실험적으로 확인 하였다(실험예 1 및 실험예 5). 또한, 본 발명의 혼합 추출물을 조골세포 유사 세포(MG-63 cell)에 처리한 경우 조골세포의 증식이 촉진되고, 이와 반대로 파골세포 에서는 증식을 억제 한다는 것을 실험적으로 확인 하였다(실험예 2 내지 4).According to one embodiment, it was confirmed that the viability of cells was improved by treating the mixed extract of the present invention on a breast cancer cell line (MCF-7 cell line), and as a result of directly taking the extract of the present invention using the Kupperman index, It was confirmed experimentally that the menopausal symptoms were improved (Experimental Example 1 and Experimental Example 5). In addition, it was experimentally confirmed that when the mixed extract of the present invention was treated with osteoblast-like cells (MG-63 cells), the proliferation of osteoblasts was promoted and, conversely, the proliferation of osteoclasts was inhibited (Experimental Examples 2 to 4). ).
상기 '약학 조성물'은 인간을 포함한 동물의 질병을 진단, 치료, 경감, 처치 또는 예방을 목적으로 사용하는 조성물을 의미한다.The 'pharmaceutical composition' refers to a composition used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of animals including humans.
상기 조성물에 포함되는 상기 혼합 추출물의 함량은 갱년기 증상 또는 골다공증을 예방, 개선 또는 치료할 수 있다면 다양한 중량%로 포함될 수 있다. 구체적으로 전체 조성물에 대하여, 갈근 추출물은 0.001 내지 30 중량%, 지각 추출물은 0.001 내지 30 중량%를 포함할 수 있다. 각 유효성분이 하한 미만으로 포함되는 경우에는 여성 갱년기 증상 예방 또는 치료 효능이 발휘되지 않을 수 있으며, 상한 초과로 포함되는 경우에는 유효성분 자체의 물성, 색 및 특유의 향미가 제품에 영향을 줄 수 있다.The content of the mixed extract included in the composition may be included in various weight % if it can prevent, improve or treat menopausal symptoms or osteoporosis. Specifically, with respect to the entire composition, the extract of the ginseng root may contain 0.001 to 30% by weight, and the crust extract may include 0.001 to 30% by weight. When each active ingredient is included below the lower limit, the efficacy of preventing or treating female menopausal symptoms may not be exhibited, and when included above the upper limit, the physical properties, color, and unique flavor of the active ingredient itself may affect the product. .
또한, 본 발명의 약학적 조성물은 단독으로 또는 갱년기 증상 및/또는 골다공증에 예방 또는 치료 효과를 나타내는 기타 약학적 활성 화합물과 결합하거나, 적당한 집합을 이루어 사용될 수 있다.In addition, the pharmaceutical composition of the present invention may be used alone or in combination with other active pharmaceutically active compounds exhibiting a preventive or therapeutic effect on menopausal symptoms and/or osteoporosis, or in an appropriate group.
본 발명의 조성물은 약학적으로 유효한 양으로 투여한다. 상기 약학적으로 유효한 양은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미하며, 유효 용량 수준은 환자의 건강상태, 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 구체적으로 투여 개체의 몸무게 1kg 당 일반적으로 1일 0.01mg 내지 5000mg이며, 의사 또는 약사의 판단에 따라 일정 시간간격으로 1일 1회 내지 수회로 분할 투여할 수도 있으나, 이에 제한되지 않는다.The composition of the present invention is administered in a pharmaceutically effective amount. The pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment and not to cause side effects, and the effective dose level is determined by the patient's health condition, disease type, severity, The activity of the drug, sensitivity to the drug, administration method, administration time, administration route and excretion rate, treatment period, factors including drugs used in combination or concurrently, and other factors well known in the medical field may be determined according to factors. Specifically, it is generally 0.01 mg to 5000 mg per day per 1 kg of the body weight of the administered subject, and may be administered in divided doses once or several times a day at regular time intervals according to the judgment of a doctor or pharmacist, but is not limited thereto.
상기 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 비경구, 경구 등의 다양한 경로로 투여될 수 있으며, 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내(intracerebroventricular) 주사에 의해 투여될 수 있다.The composition may be administered to mammals such as rats, mice, livestock, and humans by various routes such as parenteral and oral administration, and all modes of administration can be expected, for example, oral, rectal or intravenous, intramuscular , by subcutaneous, intrauterine intrathecal or intracerebroventricular injection.
본 발명의 약학적 조성물은 유효성분으로 하는 상기 추출물을 단독으로 포함할 수 있고, 이외 제형, 사용방법 및 사용목적에 따라 약학적으로 허용 가능한 담체, 부형제, 희석제 및/또는 부성분을 더 포함할 수 있다. The pharmaceutical composition of the present invention may include the above extract as an active ingredient alone, and may further include a pharmaceutically acceptable carrier, excipient, diluent and/or sub-component according to the formulation, method of use, and purpose of use. have.
보다 구체적으로, 상기 유효성분 외에 추가로 영양제, 비타민, 전해질, 풍미제, 착색제, 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 추가로 함유할 수 있다.More specifically, in addition to the above active ingredients, nutrients, vitamins, electrolytes, flavoring agents, coloring agents, thickeners, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, It may further contain glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like.
상기 '약학적으로 허용되는'이란 생리학적으로 허용되고 동물, 바람직하게는 인간에게 투여될 때, 통상적으로 위장 장애, 현기증과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 것을 의미한다. 상기 약학적으로 유효한 양은 질환 및 이의 중증 정도, 환자의 연령, 체중, 건강상태, 성별, 투여경로 및 치료기간 등에 따라 적절히 변화될 수 있다.The 'pharmaceutically acceptable' means that when it is physiologically acceptable and administered to an animal, preferably a human, it does not usually cause an allergic reaction such as gastrointestinal disorder, dizziness, or a reaction similar thereto. The pharmaceutically effective amount may be appropriately changed depending on the disease and its severity, the age, weight, health status, sex, administration route, and treatment period of the patient.
상기 약학적으로 허용되는 담체, 부형제 또는 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유, 덱스트린, 칼슘카보네이트, 덱스트린, 칼슘카보네이드, 프로필렌글리콜, 리퀴드 파라핀 및 생리식염수로 이루어진 군에서 선택된 1 이상을 들 수 있으나, 이에 한정되는 것은 아니며 통상의 담체, 부형제 또는 희석제 모두 사용 가능하다.Examples of the pharmaceutically acceptable carrier, excipient or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, propylhydroxybenzoate, talc, magnesium stearate and mineral oil , dextrin, calcium carbonate, dextrin, calcium carbonate, propylene glycol, liquid paraffin and at least one selected from the group consisting of physiological saline, but is not limited thereto, and all common carriers, excipients or diluents can be used.
상기 성분들은 상기 유효성분인 추출물에 독립적으로 또는 조합하여 추가될 수 있다. The ingredients may be added independently or in combination to the active ingredient, the extract.
상기 약학 조성물의 제형은 사용방법에 따라 달라질 수 있으며, 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 본 발명이 속하는 기술 분야에 잘 알려진 방법을 사용하여 제형화 될 수 있다. 상기 제형의 예로 연고, 크림, 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 수용액, 비수성용제, 현탁제 및 유제로 구성되는 군으로부터 선택되는 제형을 일 수 있다.The formulation of the pharmaceutical composition may vary depending on the method of use, and may be formulated using a method well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. can Examples of the formulation include ointments, creams, tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, aqueous solutions, non-aqueous solutions, suspensions and emulsions. It may be a formulation selected from the group consisting of .
상기 제형을 위하여 부형제, 일 예로 통상의 충진제, 증량제, 결합제, 붕해제, 계면활성제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제, 감미제, 방향제 또는 보존제 등을 더욱 포함할 수 있다.For the formulation, excipients, for example, conventional fillers, extenders, binders, disintegrants, surfactants, anti-aggregants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, sweeteners, fragrances or preservatives may be further included.
일반적으로는, 경구 투여를 위한 고형제제에는 정제(TABLETS), 알약, 연질 또는 경질 캅셀제(CAPSULES), 환제(PILLS), 산제(POWDERS) 및 과립제(GRANULES) 등이 포함되고, 이러한 제제는 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다.In general, solid preparations for oral administration include tablets (TABLETS), pills, soft or hard capsules (CAPSULES), pills (PILLS), powders (POWDERS), and granules (GRANULES), and such preparations include one or more An excipient, for example, may be prepared by mixing starch, calcium carbonate, sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
또한, 경구 투여를 위한 액상제제에는 현탁제(SUSTESIONS), 내용액제, 유제(EMULSIONS) 및 시럽제(SYRUPS) 등이 해당되는데, 흔히 사용되는 단순 희석제인 물 또는 리퀴드 파라핀 이외에 여러 가지 부형제 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.In addition, liquid formulations for oral administration include suspensions (SUSTESIONS), internal solutions, emulsions (EMULSIONS), and syrups (SYRUPS). In addition to water or liquid paraffin, which are commonly used simple diluents, various excipients, for example, Wetting agents, sweetening agents, flavoring agents, preservatives, and the like may be included.
피부 투여를 위해 언급할 수 있는 예로는 더스팅 파우더, 에멀젼, 현탁액, 오일, 스프레이, 연고, 그리지 연고, 크림 페이스트, 겔, 폼, 또는 용액을 생성시키는데 적합하고, 경피 약물 전달체(TTS: Transdermal therapeuticsystem)에 적합한 담체 및/또는 부형제가 있다. 본 발명의 국소용 약학제제는 반고체상 제형일 수 있으며 특히 연고(용액 연고, 현탁액 연고), 크림, 겔 또는 페이스트가 있다. 유상에 주로 사용되는 것은 지방 알콜, 예를 들면 라우릴 알코올, 세틸 알코올, 스테아릴 알코올, 지방산, 예를 들면 팔미트산 또는 스테아르산, 액상 또는 고체상 파라핀 또는 오조케라이트, 액상 내지 고체상 왁스, 예를 들면 이소프로필 미리스테이트, 천연 지방 또는 일부 합성 지방, 예를 들면 코코넛 지방산 트리글리세라이드, 경화유, 예를 들면 수소화된 피넛 또는 캐스터 오일, 또는 글리세롤의 지방산 부분 에스테르, 예를 들면 글리세롤 모노스테아레이트 또는 글리세롤 디스테아레이트가 있다. 적합한 유화제로는 계면활성제, 예를 들어 비이온성 계면활성제, 예를 들면 폴리알코올 또는 이것의 산화에틸렌 부가물의 지방산 에스테르, 예컨대 폴리글리세롤 지방산 에스테르 또는 폴리옥시에틸렌 소르비탄 지방산 에스테르, 소르비탄 지방산 에스테르, 예컨대 소르비탄 올레에이트 및/또는 소르비탄 이소스테아레이트 등, 이소스테아레이트, 스테롤, 또는 폴리옥시에틸렌 지방 알콜 에테르 또는 지방산 에스테르, 예를 들어 음이온성 계면활성제, 예를 들면 지방 알코올 설포네이트의 알칼리 금속염, 예컨대 나트륨 라우릴 설페이트, 나트륨 세틸 설페이트 또는 나트륨 스테아릴 설페이트가 있으며 이들은 상기 지방 알코올, 예를 들면 세틸 알코올 또는 스테아릴 알코올의 존재 하에서 일반적으로 사용된다. 이 중에서도 특히 크림 건조를 방지하는 제제, 예를 들면 폴리알코올, 예컨대 글리세롤, 소르비톨, 프로필렌 글리콜 및/또는 폴리에틸렌 글리콜을 수상에 첨가하거나 또는 보존제, 향료 등을 수상에 첨가하는 것이 가능하다.Examples that may be mentioned for dermal administration include dusting powders, emulsions, suspensions, oils, sprays, ointments, greasy ointments, cream pastes, gels, foams, or suitable for producing solutions, Transdermal therapeutic system (TTS) ) suitable carriers and/or excipients. The topical pharmaceutical preparation of the present invention may be in a semi-solid dosage form, and in particular, there are ointments (solution ointments, suspension ointments), creams, gels or pastes. Mainly used in the oil phase are fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, fatty acids such as palmitic or stearic acid, liquid or solid paraffin or ozokerite, liquid to solid waxes, such as for example isopropyl myristate, natural fats or some synthetic fats such as coconut fatty acid triglycerides, hydrogenated oils such as hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol such as glycerol monostearate or glycerol Distearate is present. Suitable emulsifiers include surfactants, for example nonionic surfactants, for example fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, such as sorbitan oleate and/or sorbitan isostearate and the like, isostearates, sterols, or polyoxyethylene fatty alcohol ethers or fatty acid esters such as anionic surfactants such as alkali metal salts of fatty alcohol sulfonates, Examples include sodium lauryl sulfate, sodium cetyl sulfate or sodium stearyl sulfate, which are commonly used in the presence of the fatty alcohol, for example cetyl alcohol or stearyl alcohol. Among these, it is possible to add to the aqueous phase an agent, for example, a polyalcohol, such as glycerol, sorbitol, propylene glycol and/or polyethylene glycol, which in particular prevents drying of the cream, or a preservative, a flavoring agent, etc., to the aqueous phase.
본 발명의 약학제제는 무수상태의 연고일 수 있고, 국소용도에 적합하고 체온상태에서 액체인 파라핀, 특히 저점도 파라핀을 함유하거나, 또는 상기 천연지방 또는 부분합성 지방, 예를 들면, 코코넛 지방산 트리글리세라이드, 경화유, 예를 들면 수소화된 피넛 도는 캐스터 오일, 글리세롤의 지방산 부분 에스테르, 예를 들면 글리세롤 모노스테아레이트 및 디스테아레이트, 실리콘, 예를 들면 폴리메틸실록산, 예컨대 헥사메틸디실록산 또는 옥타메틸트리실록산을 함유할 수 있으며, 예를 들어 수성크림과 관련되어 있고 수분 흡수 용량을 증가시키는 지방알코올, 그리고 스테롤, 울 왁스, 다른 유화제 및/또는 기타 첨가제를 함유할 수 있다.The pharmaceutical preparation of the present invention may be an anhydrous ointment, suitable for topical use and containing paraffin, particularly low-viscosity paraffin, which is liquid at body temperature, or the natural or partially synthetic fat, for example, coconut fatty acid triglyceride. Cerides, hydrogenated oils such as hydrogenated peanut or castor oil, fatty acid partial esters of glycerol such as glycerol monostearate and distearate, silicones such as polymethylsiloxanes such as hexamethyldisiloxane or octamethyltri It may contain siloxanes, for example fatty alcohols associated with water-based creams and increasing the water absorption capacity, and sterols, wool waxes, other emulsifiers and/or other additives.
본 발명에 있어서, 상기 약학적 조성물을 의약품으로 제형화할 경우 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 내용을 참조할 수 있고, 상기 문헌들은 본 명세서의 일부로서 포함된다.In the present invention, when the pharmaceutical composition is formulated as a pharmaceutical, reference may be made to the contents disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and the documents are incorporated as a part of this specification.
상기 약학적 조성물은 의약외품 조성물 일 수 있다. The pharmaceutical composition may be a quasi-drug composition.
본 발명의 용어 "의약외품"은 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적으로 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 사람이나 동물의 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품을 의미하며, 구체적으로 피부 외용제 또는 개인위생용품일 수 있으나, 이에 제한되지 않는다.As used herein, the term "quasi-drug" refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating or preventing diseases of humans or animals, have weak action on the human body or do not directly act on the human body, Non-machines and similar products, which are products that are used for sterilization, insecticide and similar purposes to prevent infection, and are used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals. Items that are not instruments, machines, or devices, and items used for the purpose of pharmacologically affecting the structure and function of humans or animals, other than those that are not instruments, machines, or devices, specifically, external preparations for skin or individuals It may be a hygiene product, but is not limited thereto.
본 발명의 혼합 추출물 또는 분획물을 갱년기 증상 또는 골다공증의 예방 또는 치료를 목적으로 의약외품 조성물에 첨가할 경우, 상기 추출물 또는 분획물을 그대로 첨가하거나 다른 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합량은 사용 목적에 따라 적합하게 결정할 수 있다. When the mixed extract or fraction of the present invention is added to a quasi-drug composition for the purpose of preventing or treating menopausal symptoms or osteoporosis, the extract or fraction may be added as it is or used together with other quasi-drug components, and appropriately according to a conventional method Can be used. The mixing amount of the active ingredient can be appropriately determined according to the purpose of use.
상기 피부 외용제는 특별히 이에 제한되지 않으나, 예를 들어 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 겔제 또는 젤의 형태로 제조되어 사용될 수 있다. 상기 개인위생용품에는 특별히 이에 제한되지 않으나, 구체적으로는 비누, 화장품, 물티슈, 휴지, 샴푸, 피부 크림, 얼굴 크림, 치약, 립스틱, 향수, 메이크업, 파운데이션, 볼터치, 마스카라, 아이섀도우, 선스크린 로션, 모발 손질 제품, 에어프레쉬너 겔 또는 세정 겔일 수 있다. 또한, 본 발명의 의약외품 조성물의 또 다른 예로 소독청결제, 샤워폼, 물티슈, 세제비누, 핸드워시, 마스크 또는 연고제가 있다.The external preparation for skin is not particularly limited thereto, but may be prepared and used in the form of, for example, ointment, lotion, spray, patch, cream, powder, suspension, gel, or gel. The personal care products are not particularly limited thereto, but specifically, soap, cosmetics, wet wipes, toilet paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, makeup, foundation, ball touch, mascara, eye shadow, sunscreen It may be a lotion, a hair care product, an air freshener gel or a cleansing gel. In addition, another example of the quasi-drug composition of the present invention is a disinfectant cleaner, shower foam, wet tissue, detergent soap, hand wash, mask or ointment.
또한 본 발명의 약학적 조성물은 개선, 완화, 치료 또는 예방을 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.In addition, the pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, hormone therapy, drug therapy, and biological response modifiers for improvement, alleviation, treatment or prevention.
본 발명은 상기 갱년기 증상 또는 골다공증 예방 또는 치료용 조성물을 개체에게 투여하는 단계를 포함하는 갱년기 증상 또는 골다공증 예방 또는 치료 방법을 제공한다The present invention provides a method for preventing or treating menopausal symptoms or osteoporosis, comprising administering the composition for preventing or treating menopausal symptoms or osteoporosis to an individual
본 발명의 용어 '갱년기 증상', '갱년기 골다공증', '예방', '치료' 및 '투여'는 상기에서 설명한 바와 같다.As used herein, the terms 'menopausal symptoms', 'menopausal osteoporosis', 'prevention', 'treatment' and 'administration' are the same as described above.
상기 투여를 위한 투여량, 투여 빈도 및 투여 경로는 전술한 바와 같다.The dosage, administration frequency, and administration route for the administration are the same as described above.
본 발명의 용어 '개체'란, 상기 갱년기 증상 또는 골다공증이 발병하였거나 발병할 수 있는 인간을 포함한 원숭이, 소, 말, 양, 돼지, 닭, 칠면조, 메추라기, 고양이, 개, 마우스, 쥐, 토끼 또는 기니아 피그를 포함한 모든 동물을 의미하고, 본 발명의 조성물을 개체에게 투여함으로써 상기 질환을 효과적으로 예방 또는 치료할 수 있다. As used herein, the term 'individual' refers to a monkey, cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or It means all animals, including guinea pigs, and can effectively prevent or treat the disease by administering the composition of the present invention to an individual.
또한, 본 발명에 따른 상기 조성물은 화장료 조성물 일 수 있다. In addition, the composition according to the present invention may be a cosmetic composition.
상기 화장료 조성물은 갱년기 증상 또는 골다공증의 예방 또는 개선용 일 수 있다. 구체적으로 갱년기에 의하여 나타나는 피부건조 또는 안면홍조 등의 증상을 개선 또는 예방하기 위한 것 일 수 있다. The cosmetic composition may be for preventing or improving menopausal symptoms or osteoporosis. Specifically, it may be for improving or preventing symptoms such as dry skin or hot flushes caused by menopause.
본 발명의 '갱년기 증상', '갱년기 골다공증', '개선' 및 '예방'은 상기에서 설명한 바와 같다. The 'menopausal symptoms', 'menopausal osteoporosis', 'improvement' and 'prevention' of the present invention are as described above.
본 발명의 조성물에 포함되는 상기 추출물의 유효량은 조성물이 제품화되는 형태, 상기 추출물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 수 있다. The effective amount of the extract included in the composition of the present invention may vary depending on the form in which the composition is commercialized, how the extract is applied to the skin, and the time it stays on the skin.
일 예로, 상기 조성물이 피부과적 치료를 위한 의약품으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 추출물을 포함할 수 있다. 화장품으로 제품화되는 경우에 있어서도 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워시-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 추출물을 포함할 수 있다. 반면 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워시-오프 타입의 화장품에 비해 낮은 농도의 추출물을 포함해도 무방할 것이다.For example, when the composition is commercialized as a pharmaceutical for dermatological treatment, the extract may be included at a higher concentration than when commercialized as a cosmetic that is applied to the skin on a daily basis. Even when commercialized as cosmetics, in the case of wash-off type cosmetics, such as makeup removers and detergents, in which active ingredients stay on the skin within a short period of time, a relatively high concentration of extract may be included. On the other hand, in the case of leave-on type cosmetics, such as lotions, emulsions, creams, and essences, in which active ingredients stay on the skin for a long time, it may be okay to include a lower concentration of extracts compared to wash-off type cosmetics. .
또한, 상기 조성물은 피부 외용제로 사용될 수 있다.In addition, the composition may be used as an external preparation for skin.
상기 조성물은 외피에 적용될 수 있는 어떠한 제형으로도 이용 할 수 있다. 구체적인 예로 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 파운데이션, 화장수류, 화장연고, 스프레이, 팩, 선 스크린, 메이크업 베이스, 파우더, 메이크업 제거제 및 세정제로 구성되는 군으로부터 선택되는 제형을 가질 수 있으며, 상기 예에 제한되지 않는다.The composition can be used in any formulation that can be applied to the skin. Specific examples include solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, foundations, lotions, cosmetic ointments, sprays, packs, sunscreens, makeup bases, powders, makeup It may have a formulation selected from the group consisting of a remover and a cleaning agent, but is not limited to the above examples.
본 발명에 따른 추출물을 함유하는 화장료 조성물은 사용 및 취급이 용이하도록 화장학적으로 허용되는 담체, 희석제, 보조제, 착색제, 안정화제, 착향제, 계면활성제, 유분, 보습제, 알코올, 점증제, 산화방지제, pH 조절제, 자외선 차단제 등을 추가로 함유할 수 있고, 피부외용 조성물로 사용될 때에는 액상, 유상, 크림상, 연고, 스틱상, 팩, 파스타제, 산제 등 외피에 적용할 수 있는 어떠한 제형으로도 이용 가능하다. 또한, 이들을 단독 또는 2종 이상 포함할 수 있다.The cosmetic composition containing the extract according to the present invention is a cosmetically acceptable carrier, diluent, adjuvant, colorant, stabilizer, flavoring agent, surfactant, oil, humectant, alcohol, thickener, antioxidant for easy use and handling. , pH adjuster, sunscreen, and the like, and when used as an external composition for skin, any formulation that can be applied to the skin, such as liquid, oil, cream, ointment, stick, pack, pasta, powder, etc. Available. In addition, these may be included alone or two or more types.
상기 화장료 조성물을 화장품으로 제형화 할 경우 활성 성분에 대한 담체로서 작용하는 피부적으로 허용 가능한 공지의 부형제를 포함할 수 있고, 구체적으로 International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995에 개시되어 있는 내용을 참조할 수 있다. 상기 문헌들은 본 명세서의 일부로서 포함된다.When the cosmetic composition is formulated as a cosmetic, it may contain a known dermatologically acceptable excipient acting as a carrier for the active ingredient, specifically, International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association , Inc., Washington, 1995 may be referred to. These documents are incorporated as part of this specification.
또한 본 발명은 혼합 추출물을 유효성분으로 포함하는 화장품에 관한 것이다. In addition, the present invention relates to a cosmetic comprising a mixed extract as an active ingredient.
상기 화장품은 화장수류, 에센스류, 스킨류, 로션류, 크림류, 팩류로 이루어진 군으로부터 선택된 어느 하나의 제형을 갖는 것 일 수 있다.The cosmetics may have any one formulation selected from the group consisting of lotions, essences, skins, lotions, creams, and packs.
상기 화장품은 일 예로 스킨, 스킨소프트너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림 모이스쳐크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클렌저 등이 있으나, 이에 한정되는 것은 아니다.The cosmetics include, for example, skin, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream, foundation, essence, nourishing essence, pack, cleansing foam, There are cleansing lotions, cleansing creams, body lotions and body cleansers, but is not limited thereto.
이상 본 명세서에 기재된 수치 값은 달리 명시되어 있지 않은 한 균등범위까지 포함하는 것으로 해석되어야 한다.Numerical values described in the above specification should be interpreted as including equivalent ranges unless otherwise specified.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석돼서는 안 된다. 본 발명의 실시예들은 당 업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples and the like will be described in detail to help the understanding of the present invention. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.
[[ 실시예Example ]]
제조예manufacturing example 1. One. In vitroin vitro 평가시 추출물의 제조 Preparation of extracts upon evaluation
하기 실시예에 사용한 추출물은 에탄올 추출물로, ㈜ 오비엠랩에서 구입하여 사용하였으며, 추출물은 원재료와 100% 주정을 혼합하는 원료 투입과정, 상온에서 추출하는 과정, 불순물을 제거하는 여과과정, 고형분이 85%가 되도록 농축하는 과정을 통해 제조하여, 인비트로(in vitro) 세포 실험에 사용하였다.The extract used in the following examples was an ethanol extract, which was purchased from OBM Lab Co., Ltd. and used. The extract is a raw material input process of mixing raw materials and 100% alcohol, extraction process at room temperature, filtration process to remove impurities, solid content It was prepared through a process of concentration to 85%, and used for in vitro cell experiments.
제조예manufacturing example 2. 2. 쿠퍼만지수Cooperman's index 임상평가용 연질 캡슐 제조 Manufacturing of soft capsules for clinical evaluation
임상평가용 연질 캡슐의 제조과정은 크게 주원료(갱년기 소재)를 만드는 과정과 연질 캡슐을 만드는 과정으로 나누어 수행하였다. The manufacturing process of soft capsules for clinical evaluation was largely divided into the process of making the main raw material (menopausal material) and the process of making the soft capsule.
우선 주원료는 갈근의 건조 분말 시료에 10배량의 정제수를 가한 후, 추출장치를 이용하여 80 ℃에서 6시간 추출하였다. 상기 추출액을 지름 160mm의 여과지를 이용하여 여과를 수행하고, 여과된 추출액을 감압 농축한 후, 동결건조를 수행하여 분말상태의 추출물을 제조하였다. 지각도 동일한 방법으로 추출물을 제조 하였다. First, as the main raw material, 10 times the amount of purified water was added to the dry powder sample of brown root, and then extracted at 80° C. for 6 hours using an extraction device. The extract was filtered using a filter paper having a diameter of 160 mm, and the filtered extract was concentrated under reduced pressure, followed by freeze-drying to prepare a powdery extract. The crust was prepared in the same way as the extract.
그 후 주원료인 갱년기 소재와 부형제인 대두유, 밀납, 대두레시틴 d-알파 토코페롤을 혼합 교반 한 후 기포를 제거하여 연질캡슐의 내용물을 제조하고, 정제수와 색소, 글리세린, 변성전분, 카라기난을 교반하여 캡슐기제를 제조한 다음, 캡슐기제에 내용물을 중량에 맞추어 충전 및 성형 후 건조하여 연질 캡슐을 제조하였다. 구체적인 연질 캡슐 내용물의 함량비는 하기 표 1에 기재된 바와 같다.After that, the main raw material for menopause and excipients such as soybean oil, beeswax, and soybean lecithin d-alpha tocopherol are mixed and stirred to remove air bubbles to prepare the contents of the soft capsule, and purified water, color, glycerin, modified starch, and carrageenan are stirred to make the capsules. After preparing the base, the contents of the capsule base were filled and molded according to the weight, and then dried to prepare a soft capsule. Specific content ratios of the contents of the soft capsules are as shown in Table 1 below.
실험예Experimental example 1. One. MCFMCF -7 세포에 대한 세포 활성도(Cell Viability) 측정-7 Cell Viability Measurement for Cells
에스트로겐 수용체 양성 인간 유방암 세포주인 MCF-7 세포주에 대한 추출물의 세포 활성도(Cell Viability)를 측정하였다. MCF-7 세포를 이용한 CCK-8 분석은 시료 내 천연유래 여성 호르몬이 여성에게 미칠 수 있는 효능을 확인할 수 있는 실험법이다. Cell viability of the extract against the estrogen receptor-positive human breast cancer cell line, the MCF-7 cell line, was measured. CCK-8 analysis using MCF-7 cells is an experimental method that can confirm the effect that naturally-derived female hormones in a sample can have on women.
MCF-7 세포를 10% FBS가 첨가된 DMEM 배지를 사용하여 96 well plate에서 배양하였다. 24시간 배양 후, 음성대조군(무처리군, control)과 양성대조군(Estradiol 처리군, E2)으로 나누고, 실험군에는 갈근 추출믈, 지각 추출물을 개별 처리 또는 갈근 및 지각 추출물을 혼합 처리하였으며, 72시간 후에 CCK-8을 이용하여 세포 활성도(Cell Viability)를 측정하였다. 배지 100 ㎕당 CCK-8시약을 10 ㎕처리하고 1시간 후 450nm에서 흡광도를 측정하였다. 그 결과를 도 1에 나타내었다. MCF-7 cells were cultured in 96 well plate using DMEM medium supplemented with 10% FBS. After culturing for 24 hours, it was divided into a negative control group (untreated group, control) and a positive control group (Estradiol treatment group, E2). Afterwards, using CCK-8, cell viability was measured. 10 μl of CCK-8 reagent per 100 μl of medium was treated, and absorbance was measured at 450 nm after 1 hour. The results are shown in FIG. 1 .
도 1에 나타낸 바와 같이, 갈근 및 지각을 각각 단독 추출물로 처리하였을 때도 무처리군 보다 세포 활성도가 높았으나, 각 추출물의 단독 처리 보다, 갈근과 지각 추출물을 혼합하여 처리했을 때 세포 활성도(Cell Viability)가 다른 처리군과 비교해서도 현저하게 증진되는 것을 확인하였다. As shown in FIG. 1 , the cell activity was higher than that of the untreated group when each extract was treated with each extract, but the cell viability (Cell Viability) when the extracts were mixed with each extract was higher than that of each extract alone. ) was significantly improved compared to other treatment groups.
실험예Experimental example 2. 조골세포 증식촉진 효과 2. Osteoblast proliferation promoting effect
조골세포 증식촉진 효과를 확인하기 위하여 인간 조골세포-유사 MG-63세포(human osteoblast-like MG-63 cell)에서 CCK-8 assay를 수행하였다. CCK-8 assay was performed on human osteoblast-like MG-63 cells to confirm the osteoblast proliferation promoting effect.
실험군으로는 음성대조군(무처리군, control)과 양성대조군 (Estradiol 처리군, E2), 각각의 단독 추출물 처리군(갈근 추출물, 지각 추출물) 그리고 혼합 추출물 처리군(갈근+지각 추출물)으로 하여 실험을 수행하였다Experiments were conducted with a negative control group (untreated group, control) and a positive control group (Estradiol treatment group, E2), each individual extract treatment group (P. was performed
먼저, 균일한 수의 MG-63 세포를 10% FBS가 첨가된 EMEM 배지를 사용하여 96 well plate에서 배양하였다. 24시간 배양 후, FBS가 없는 EMEM 배지로 교체하고, 음성대조군(무처리군, control), 양성대조군 (Estradiol 처리, E2), 갈근 추출물, 지각 추출물을 각각 단독 처리하고, 갈근과 지각을 1:1로 혼합하여, 상기 혼합 추출물을 각각 처리 하였다. 처리 48시간 후, CCK-8을 이용하여 세포 활성도(Cell Viability)를 측정하였다. 배지 100 ㎕당 CCK-8시약을 10 ㎕처리하고 1시간 후 450nm에서 흡광도를 측정하였다. 그 결과를 도 2에 나타내었다. First, a uniform number of MG-63 cells were cultured in a 96-well plate using EMEM medium supplemented with 10% FBS. After culturing for 24 hours, the medium was replaced with EMEM medium without FBS, and the negative control group (untreated group, control), the positive control group (Estradiol treatment, E2), the brown root extract and the crust extract were treated individually, respectively, and the brown root and crust were 1: 1, and each of the mixed extracts was treated. After 48 hours of treatment, cell viability was measured using CCK-8. 10 μl of CCK-8 reagent per 100 μl of medium was treated, and absorbance was measured at 450 nm after 1 hour. The results are shown in FIG. 2 .
도 2에 나타낸 바와 같이, 갈근과 지각 혼합 추출물을 처리 했을 때, 단독 추출물 처리군과 비교해서 조골세포 증식 효과가 더 우수함을 확인하였고, 혼합 추출물을 처리한 경우 양성대조군(E2 처리군)과 비교해서도 조골세포 증식 효과가 더 우수함을 확인하였다. As shown in FIG. 2 , when the mixed extract of brown root and crustaceans was treated, it was confirmed that the osteoblast proliferation effect was better than that of the single extract treatment group, and compared with the positive control group (E2 treatment group) when the mixed extract was treated It was also confirmed that the osteoblast proliferation effect was more excellent.
실험예Experimental example 3. 조골세포 분화촉진 효과 3. Osteoblast differentiation promoting effect
각 추출물의 조골세포 분화촉진 효과를 확인하기 위하여 인간 조골세포-유사 MG-63세포(human osteoblast-like MG-63 cell)에서 ALP 활성을 측정하였다. 먼저, 균일한 수의 MG-63 세포를 10% FBS가 첨가된 DMEM 배지를 사용하여 24 well plate에서 배양하였다. 24시간 배양 후, 배지를 10% charcoal stripped FBS containing phenol red free 배지(medium)로 바꿔주고 음성대조군(무처리군, control)과 양성대조군(Estradiol, E2), 갈근 추출물, 지각 추출물을 단독 처리하고, 갈근+지각 1:1로 혼합 추출물을 처리하였다.. 3일 배양 후, 동일한 배지와 동일한 추출물 농도로 한번 더 처리한 후, 3일 더 배양하였다. 총 6일 배양 후, ALP 활성 측정을 위해 SensoLyte® pNPP Alkaline Phosphatase Assay Kit(ANASPEC AS-72146)로 어세이를 수행하였다. 세포를 분석 완충액(Assay buffer)으로 두 번 세척 하고, Triton X-100이 포함된 분석 완충액(assay buffer)을 200㎕ 넣은 후, 플레이트(plate)를 얼음에 올려두어 10분간 쉐이킹 인큐베이션(shaking incubation) 하였다. 셀 서스펜션(Cell suspension)을 마이크로센트리퓨즈 튜브(microcentrifuge tube)에 옮긴 후, 4℃에서 2500 X g로 10분간 원심분리하여 상등액 50 ㎕와 pNPP 기질(substrate) 50 ㎕를 96 well plate에 넣어 30분간 반응 후, 405nm에서 흡광도를 측정하였다. 그 결과를 도 3에 나타내었다. In order to confirm the osteoblast differentiation promoting effect of each extract, ALP activity was measured in human osteoblast-like MG-63 cells. First, a uniform number of MG-63 cells were cultured in a 24-well plate using DMEM medium supplemented with 10% FBS. After culturing for 24 hours, the medium was changed to 10% charcoal stripped FBS containing phenol red free medium (medium), and the negative control group (untreated group, control) and positive control group (Estradiol, E2), brown root extract, and crust extract were treated alone. , was treated with a mixed extract at 1:1 ratio of ginseng root + crust. After culturing for 3 days, it was treated once again with the same concentration of extract in the same medium and then cultured for 3 more days. After a total of 6 days of culture, assays were performed with SensoLyte® pNPP Alkaline Phosphatase Assay Kit (ANASPEC AS-72146) to measure ALP activity. Cells are washed twice with assay buffer, 200 μl of assay buffer containing Triton X-100 is added, and the plate is placed on ice for 10 minutes shaking incubation. did. After transferring the cell suspension to a microcentrifuge tube, centrifuged at 2500 X g at 4°C for 10 minutes, and 50 μl of the supernatant and 50 μl of pNPP substrate were placed in a 96 well plate for 30 minutes. After the reaction, absorbance was measured at 405 nm. The results are shown in FIG. 3 .
도 3에 나타낸 바와 같이, 혼합 추출물을 처리한 세포의 경우 단독 처리군에 비해 조골세포 분화를 훨씬 더 촉진시키는 효능을 나타내는 것을 확인하였다.As shown in FIG. 3 , it was confirmed that the cells treated with the mixed extract exhibited the efficacy of promoting osteoblast differentiation much more than the single treatment group.
실험예Experimental example 4. 파골세포 증식 억제 효과 4. Inhibitory effect on osteoclast proliferation
각 추출물의 파골세포 증식억제 효과를 확인하기 위하여 B-bridge® Rat Primary Precursor Osteoclasts culture Kit로 파골세포를 배양한 다음 CCK-8 assay를 수행하였다. 먼저, 균일한 수의 세포를 Kit에 동봉된 배양(culture) 배지를 사용하여 96 well plate에 시딩(seeding)한 직후에 음성대조군(무처리군, control)과 양성대조군(Estradiol 처리군, E2), 갈근, 지각 단독 추출물과 갈근+지각 혼합추출물을 농도별(10, 50, 100ppm)로 처리하였다. 시료 처리 72시간 후, CCK-8을 이용하여 세포 생존력(cell viability)를 측정하였다. 배지 100 ㎕당 CCK-8시약을 10 ㎕처리하고 1시간 후 450nm에서 흡광도를 측정하였다. 그 결과를 도 4에 나타내었다. To confirm the osteoclast proliferation inhibitory effect of each extract, osteoclasts were cultured with B-bridge® Rat Primary Precursor Osteoclasts Culture Kit, and then CCK-8 assay was performed. First, a uniform number of cells were seeded in a 96-well plate using the culture medium included in the kit, and then a negative control group (untreated group, control) and a positive control group (Estradiol-treated group, E2) , Gargeun and Crustaceae alone extracts and Crustacea + Crustaceae mixed extracts were treated with different concentrations (10, 50, 100ppm). After 72 hours of sample treatment, cell viability was measured using CCK-8. 10 μl of CCK-8 reagent per 100 μl of medium was treated, and absorbance was measured at 450 nm after 1 hour. The results are shown in FIG. 4 .
도 4에 나타낸 바와 같이, 혼합 추출물을 처리한 세포의 경우 단독 추출물 처리군에 비해 파골세포 증식을 훨씬 효과적으로 억제시키는 효능을 나타내는 것을 확인하였다. 특히 처리 농도가 증가될수록 파골세포 증식을 억제하는 효과가 현저하게 상승되는 것을 확인하였다..As shown in FIG. 4 , it was confirmed that the cells treated with the mixed extract exhibited the efficacy of inhibiting osteoclast proliferation much more effectively compared to the single extract treatment group. In particular, it was confirmed that the effect of inhibiting osteoclast proliferation significantly increased as the treatment concentration increased.
실험예Experimental example 5. 갱년기 증상 완화 효과 평가 5. Evaluation of the effect of alleviating menopausal symptoms
갱년기 증상을 겪고 있는 40대 후반에서 50대의 여성 60명을 무작위로 나누어 비교예 1~4 및 실시예 1의 연질캡슐을 1일 3캡슐씩, 8주간 복용하도록 한 다음 갱년기 증상의 개선 정도를 평가하였다. 60 women in their late 40s to 50s suffering from menopausal symptoms were randomly divided and the soft capsules of Comparative Examples 1 to 4 and Example 1 were taken 3 capsules a day for 8 weeks, and then the degree of improvement in menopausal symptoms was evaluated did.
비교예 1은 추출물 미복용군, 비교예 2는 갈근 단독 추출물 복용군, 비교예 3은 지각 단독 추출물 복용군을 나타내고, 실시예 1은 갈근 및 지각의 혼합 추출물 복용군을 의미한다. Comparative Example 1 refers to a group that did not take the extract, Comparative Example 2 refers to a group that took the extract alone, Comparative Example 3 refers to a group that took the extract alone, and Example 1 refers to the group that took the mixed extract of Garlic Root and Crustaceae.
섭취 8주 후의 갱년기 증상의 개선 정도는 쿠퍼만 지수(Kupperman index)로 측정하였으며, 섭취 전의 수치를 100으로 보았을 때, 섭취 후의 상대적인 수치를 하기 표2에 나타내었다.The degree of improvement in menopausal symptoms after 8 weeks of ingestion was measured by the Kupperman index, and when the value before ingestion was taken as 100, the relative values after ingestion are shown in Table 2 below.
본 발명에서 사용된 쿠퍼만 지수(KI)는 학계에서 사용되는 갱년기 지수로서 갱년기 여성에게서 나타나는 11가지 증상(안면홍조, 발한, 불면증, 신경질, 우울증, 어지럼증, 피로감, 관절통 및 근육통, 두통, 가슴 두근거림, 질 건조)을 점수화한 것으로 각 항목의 점수에 가중치를 곱해 점수를 내고 이를 모두 더한 점수가 갱년기 점수이다. The Kupperman index (KI) used in the present invention is a menopausal index used in academia, and has 11 symptoms (hot flush, sweating, insomnia, nervousness, depression, dizziness, fatigue, joint and muscle pain, headache, and chest palpitations) that appear in menopausal women. distance, vaginal dryness) is scored, and the score of each item is multiplied by a weight to give a score, and the sum of these scores is the menopause score.
상기 표 2로부터 갈근과 지각을 혼합한 실시예1의 조성물은 각각의 추출물을 단독으로 처리했을 때보다 갱년기 증상 완화 효과가 훨씬 우수한 것을 확인하였다.From Table 2, it was confirmed that the composition of Example 1, in which the black root and crust was mixed, was much more effective in relieving menopausal symptoms than when each extract was treated alone.
삭제delete
삭제delete
Claims (23)
갈근 추출물 10중량부에 대하여,
지각 추출물을 1 내지 100 중량부로 포함하는 갱년기 증상 예방 또는 개선용 식품 조성물. The method of claim 1,
With respect to 10 parts by weight of the extract,
A food composition for preventing or improving menopausal symptoms comprising 1 to 100 parts by weight of a crust extract.
상기 추출물은 물, 탄소수 1 내지 5의 알코올, 에틸아세테이트, 아세톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상의 추출용매의 추출물 인, 조성물.3. The method according to claim 1 or 2,
The extract is an extract of one or more extraction solvents selected from the group consisting of water, alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, and chloroform.
대두유, 밀납, 레시틴 및 토코페롤로 이루어진 군에서 선택된 하나 이상의 성분을 더 포함하는, 조성물.3. The method according to claim 1 or 2,
A composition further comprising one or more components selected from the group consisting of soybean oil, beeswax, lecithin and tocopherol.
갈근 추출물 10중량부에 대하여,
지각 추출물을 1 내지 100 중량부로 포함하는 갱년기 증상 예방 또는 개선용 건강 기능 식품.6. The method of claim 5,
With respect to 10 parts by weight of the extract,
A health functional food for preventing or improving menopausal symptoms comprising 1 to 100 parts by weight of a crust extract.
상기 추출물은 물, 탄소수 1 내지 5의 알코올, 에틸아세테이트, 아세톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상의 추출용매의 추출물 인, 식품.7. The method according to claim 5 or 6,
The extract is an extract of one or more extraction solvents selected from the group consisting of water, alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone and chloroform, food.
갈근 추출물 10중량부에 대하여,
지각 추출물을 1 내지 100 중량부로 포함하는 갱년기 증상 예방 또는 치료용 약학 조성물.9. The method of claim 8,
With respect to 10 parts by weight of the extract,
A pharmaceutical composition for preventing or treating menopausal symptoms comprising 1 to 100 parts by weight of a crust extract.
상기 추출물은 물, 탄소수 1 내지 5의 알코올, 에틸아세테이트, 아세톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상의 추출용매의 추출물 인, 조성물.10. The method according to claim 8 or 9,
The extract is an extract of one or more extraction solvents selected from the group consisting of water, alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone, and chloroform.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160065101A KR102275268B1 (en) | 2016-05-26 | 2016-05-26 | Composition for relieving menopausal symptom or osteoporosis |
CN201710367241.3A CN107432889A (en) | 2016-05-26 | 2017-05-23 | Menopause symptom or osteoporosis improvement composition |
JP2017102466A JP2017209108A (en) | 2016-05-26 | 2017-05-24 | Composition for improving climacteric symptom or osteoporosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160065101A KR102275268B1 (en) | 2016-05-26 | 2016-05-26 | Composition for relieving menopausal symptom or osteoporosis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170133820A KR20170133820A (en) | 2017-12-06 |
KR102275268B1 true KR102275268B1 (en) | 2021-07-09 |
Family
ID=60458794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160065101A KR102275268B1 (en) | 2016-05-26 | 2016-05-26 | Composition for relieving menopausal symptom or osteoporosis |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2017209108A (en) |
KR (1) | KR102275268B1 (en) |
CN (1) | CN107432889A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220143572A (en) * | 2021-04-16 | 2022-10-25 | 한국생명공학연구원 | Composition for preventing or treating andropause syndrome comprising aurantii fructus immaturus as an effective component |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100851783B1 (en) * | 2007-04-16 | 2008-08-13 | 경희대학교 산학협력단 | Composition comprising an extract of mixted herbal bhh 17 for preventing and treating fractural disease |
KR101544532B1 (en) * | 2013-10-17 | 2015-08-17 | 고려대학교 산학협력단 | Composition comprising an extract of Cynanchi wilfordii for preventing or treating of climacteric disorder |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020071976A1 (en) | 2000-11-03 | 2002-06-13 | Edlund David J. | Sulfur-absorbent bed and fuel processing assembly incorporating the same |
JP2005139150A (en) * | 2003-11-10 | 2005-06-02 | Api Co Ltd | Estrogenic agent, method for producing the same, prophylactic agent for osteoporosis and food and beverage |
KR100613447B1 (en) | 2004-10-07 | 2006-08-21 | 주식회사 하이닉스반도체 | Data Latch Circuit and Semiconductor Device |
JP4805589B2 (en) * | 2005-03-02 | 2011-11-02 | 株式会社 資生堂 | Estrogenic agent |
CN101147754A (en) * | 2006-09-19 | 2008-03-26 | 郑州博凯医药科技有限公司 | Compound effervescence preparation containing pureraria root extraction |
KR101177508B1 (en) * | 2010-01-29 | 2012-08-28 | 고려대학교 산학협력단 | Composition of Pueraris lobata extracts for menopausal symptoms |
CN102579972B (en) * | 2011-12-05 | 2013-07-10 | 北京工商大学 | Traditional Chinese medicine composition and preparation with effect of relieving dark eye circles and preparation method of traditional Chinese medicine composition and preparation |
CN103816210A (en) * | 2012-11-16 | 2014-05-28 | 邢秋苓 | Pueraria lobata extract and application thereof |
CN104958607A (en) * | 2015-07-21 | 2015-10-07 | 青岛恒波仪器有限公司 | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof |
-
2016
- 2016-05-26 KR KR1020160065101A patent/KR102275268B1/en active IP Right Grant
-
2017
- 2017-05-23 CN CN201710367241.3A patent/CN107432889A/en active Pending
- 2017-05-24 JP JP2017102466A patent/JP2017209108A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100851783B1 (en) * | 2007-04-16 | 2008-08-13 | 경희대학교 산학협력단 | Composition comprising an extract of mixted herbal bhh 17 for preventing and treating fractural disease |
KR101544532B1 (en) * | 2013-10-17 | 2015-08-17 | 고려대학교 산학협력단 | Composition comprising an extract of Cynanchi wilfordii for preventing or treating of climacteric disorder |
Non-Patent Citations (1)
Title |
---|
Evidence-Based Complementary and Alternative Medicine, Vplume2014, Article ID 796518, 7pages (2014.06.12.) 1부.* |
Also Published As
Publication number | Publication date |
---|---|
CN107432889A (en) | 2017-12-05 |
KR20170133820A (en) | 2017-12-06 |
JP2017209108A (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6873517B2 (en) | Health-maintaining product composition applicable to adult women, the elderly and people in sub-health conditions | |
JP2022009308A (en) | Composition for ameliorating climacteric symptoms or osteoporosis | |
KR20110004603A (en) | Extracts from sophora japonica l. for treating or preventing menopausal complaints, skin-aging, or skin wrinkle | |
KR20180010961A (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
KR102511361B1 (en) | Composition for Preventing, Improving or Treating Postmenopausal Syndrome Comprising Rosa rugosa Thunberg Extract | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
JP2024050702A (en) | Composition for preventing or treating obesity or obesity-induced metabolic syndrome, comprising Enterococcus faecalis as an active ingredient | |
JP6981664B2 (en) | Nourishing tonic | |
KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR102465346B1 (en) | A composition comprising Chrysanthemum zawadskii and Cudrania tricuspidata Bureau having anti-inflammation activity | |
US10806766B2 (en) | Method for treating, preventing, or alleviating osteoporosis | |
KR101897720B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth comprising Tenebrio molitor fractions | |
EP3449736B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR20120111125A (en) | Composition for treatment of renal cell carcinoma and functional food comprising extract of cannabis semen | |
KR20210003999A (en) | Composition for preventing or treating rheumatoid arthritis comprising venom derived from Agkistrodon piscivorous piscivorous | |
KR20150120741A (en) | Composition for preventing or improving atopic dermatitis comprising mixture of persimmon peel, persimmon flesh, persimmon leaf and Diospyros lotus leaf as effective component | |
WO2021020857A1 (en) | Use of composition for prevention, alleviation or treatment of bone loss disorders, containing extracts of reynoutria japonica and cassiae cortex interior | |
KR20170133821A (en) | Composition for relieving hot flush or osteoporosis | |
KR20210002037A (en) | A composition for preventing, improving or treating pain comprising olive leaf and citrus pericarp extract | |
KR20160071523A (en) | A composition for preventing hair loss and stimulating hair growth comprising Poncirus trifoliate extract | |
KR20230096822A (en) | Composition for preventing, ameliorating or treating skin disease comprising Carpesium glossophyllum extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019101003911; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191127 Effective date: 20210202 |
|
E902 | Notification of reason for refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant |